Podocytes, glucose and insulin

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 4, 2010, Pages 379-384

  Welsh, Gavin I ^a   Coward, Richard J M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

diabetes; glucose; insulin; insulin resistance; metabolic syndrome; podocytes

Indexed keywords

GLUCOSE; INSULIN; NEPHRIN;

ALBUMINURIA; APOPTOSIS; BASEMENT MEMBRANE; CELL DAMAGE; CELL FUNCTION; CELL LOSS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; REVIEW; ANIMAL; CHRONIC KIDNEY FAILURE; DIABETIC NEUROPATHIES; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; GLUCOSE; HUMANS; INSULIN; KIDNEY; KIDNEY FAILURE, CHRONIC; PODOCYTES;

EID: 77954084633     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833ad5e4     Document Type: Review

References (57)

1. Lavin PJ, Gbadegesin R, Damodaran TV, Winn MP. Therapeutic targets in focal and segmental glomerulosclerosis. Curr Opin Nephrol Hypertens 2008; 17:386-392.
2. Brown EJ, Schlondorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010; 42:72-76.
3. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55:225-233.
4. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13:1349-1358.
5. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54:1626-1634.
6. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99:342-348.
7. White KE, Bilous RW, Marshall SM, et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002; 51:3083-3089.
8. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999; 42:1341-1344.
9. Lewko B, Stepinski J. Hyperglycemia and mechanical stress: targeting the renal podocyte. J Cell Physiol 2009; 221:288-295.
10. Eid AA, Gorin Y, Fagg BM, et al. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 2009; 58:1201-1211.
11. D'Agati V, Yan SF, Ramasamy R, Schmidt AM. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol Metab 2010; 21:50-56.
12. Chuang PY, Yu Q, Fang W, et al. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int 2007; 72:965-976.
13. Durvasula RV, Shankland SJ. Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol 2008; 294:F830-839.
14. Lee SH, Yoo TH, Nam BY, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol 2009; 297:F1381-F1390.
15. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF: a signaling pathway in the glomerulus-evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007; 106:32-37.
16. Rask-Madsen C, King GL. Kidney complications: factors that protect the diabetic vasculature. Nat Med 2010; 16:40-41.
17. Muller-Deile J, Worthmann K, Saleem M, et al. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol 2009; 297:F1656-F1667.
18. Qiu Y, Hoareau-Aveilla C, Oltean S, et al. The antiangiogenic isoforms of VEGF in health and disease. Biochem Soc Trans 2009; 37 (Pt 6):1207-1213.
19. Kimura M, Toyoda M, Kato M, et al. Expression of alpha-actinin-4 in human diabetic nephropathy. Intern Med 2008; 47:1099-1106.
20. Schordan S, Schordan E, Endlich N, et al. Alterations of the podocyte proteome in response to high glucose concentrations. Proteomics 2009; 9:4519-4528.
21. Coward RJ, Welsh GI, Yang J, et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54:3095-3102.
22. Tejada T, Catanuto P, Ijaz A, et al. Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int 2008; 73:1385-1393.
23. Lennon R, Pons D, Sabin MA, et al. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy. Nephrol Dial Transplant 2009; 24:3288-3296.
24. D'Apolito M, Du X, Zong H, et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest 2010; 120:203-213.
25. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366:1059-1062. (Pubitemid 41338752)
26. Shepherd PR, Kahn BB. Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. N Engl J Med 1999; 341:248-257.
27. Jauregui A, Mintz DH, Mundel P, Fornoni A. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens 2009; 18:539-545.
28. Hadjadj S, Pean F, Gallois Y, et al. Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study. Diabetes Care 2004; 27:2661-2668.
29. Orchard TJ, Chang YF, Ferrell RE, et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002; 62:963-970.
30. SharmaK, RamachandraraoS, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118:1645-1656.
31. Suganami T, Mukoyama M, Mori K, et al. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J 2005; 19:127-129.
32. Ijaz A, Tejada T, Catanuto P, et al. Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int 2009; 75:381-388.
33. Lennon R, Welsh GI, Singh A, et al. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1. Diabetologia 2009; 52:1944-1952.
34. Ohtomo S, Izuhara Y, Takizawa S, et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007; 72:1512-1519.
35. Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000; 49:1022-1032.
36. Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 2001; 37 (2 Part 2):722-727.
37. Zhang H, Saha J, Byun J, et al. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295:F1071-F1081.
38. Piwkowska A, Rogacka D, Jankowski M, et al. Metformin induces suppression of NAD(P)H oxidase activity in podocytes. Biochem Biophys Res Commun 2010; 393:268-273.
39. Imano E, KandaT, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21:2135-2139.
40. Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006; 24:2047-2055.
41. Ren S, Xin C, Beck KF, et al. PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun 2005; 338:1818-1824.
42. Smulders YM, van Eeden AE, Stehouwer CD, et al. Can reduction in hyper-triglyceridaemia slow progression of microalbuminuria in patients with nonin-sulin-dependent diabetes mellitus? Eur J Clin Invest 1997; 27:997-1002.
43. Park CW, Kim HW, Ko SH, et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 2006; 55:885-893.
44. Yang HC, Ma LJ, Ma J, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006; 69:1756-1764.
45. Kanjanabuch T, Ma LJ, Chen J, et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007; 71:1232-1239.
46. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009; 76:145-148.
47. Ellington AA, Malik AR, Klee GG, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007; 50:708-714.
48. Kestila M, Lenkkeri U, Mannikko M, et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1:575-582.
49. Jones N, Blasutig IM, Eremina V, et al. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature 2006; 440:818-823.
50. Jones N, New LA, Fortino MA, et al. Nck proteins maintain the adult glomerular filtration barrier. J Am Soc Nephrol 2009; 20:1533-1543.
51. Verma R, Kovari I, Soofi A, et al. Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J Clin Invest 2006; 116:1346-1359.
52. Ha TS. High-glucose and advanced glycosylation end products increased podocyte permeability via PI3-K/Akt signaling. J Mol Med 2010; 88:391-400.
53. Hussain S, Romio L, Saleem M, et al. Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol 2009; 20:1733-1743.
54. DoublierS, SalvidioG, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52:1023-1030.
55. Bonnet F, Cooper ME, Kawachi H, et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44:874-877.
56. Benigni A, Gagliardini E, Tomasoni S, et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65:2193-2200.
57. Fornoni A, Jeon J, Varona Santos J, et al. Nephrin is expressed on the surface of insulin vesicles and facilitates glucose-stimulated insulin release. Diabetes 2010; 59:190-199.